Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure

Clinical Cancer Research

Volumn 18, Issue 11, 2012, Pages 3170-3179

  Demetri, George D ^a   Garrett, Christopher R ^b   Schöffski, Patrick ^c   Shah, Manisha H ^d   Verweij, Jaap ^e   Leyvraz, Serge ^f   Hurwitz, Herbert I ^g   Pousa, Antonio Lopez ^h   Le Cesne, Axel ⁱ   Goldstein, David ^j   Paz Ares, Luis ^k,l   Blay, Jean Yves ^m   McArthur, Grant A ⁿ   Xu, Qiang ^o   Huang, Xin ^p   Harmon, Charles S ^p   Tassell, Vanessa ^p   Cohen, Darrel P ^p   Casali, Paolo G ^q  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d OHIO STATE UNIVERSITY   (United States)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j UNIVERSITY OF NEW SOUTH WALES   (Australia)

^k Instituto de Biomedicina de Sevilla   (Spain)

^l HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^m UNIVERSITÉ LYON 1   (France)

ⁿ PETER MACCALLUM CANCER CENTRE   (Australia)

^o Och Spine at New York Presbyterian Hospitals   (United States)

^p PFIZER INC   (United States)

^q NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IMATINIB; PLACEBO; SUNITINIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HAIR COLOR; HAND FOOT SYNDROME; HEADACHE; HEART DISEASE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LEUKOCYTE COUNT; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISCOLORATION; STOMATITIS; SURVIVAL TIME; THROMBOCYTE COUNT; TREATMENT DURATION; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADULT; AGED; CROSS-OVER STUDIES; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PIPERAZINES; PLACEBOS; PYRIMIDINES; PYRROLES; RETREATMENT; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84861786753     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3005     Document Type: Article

References (23)

1. Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol 2008;3:557-86. (Pubitemid 351488293)
2. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10. (Pubitemid 36159485)
3. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80. (Pubitemid 28067289)
4. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8.
5. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006;91:4070-6. (Pubitemid 44536887)
6. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37. (Pubitemid 36109749)
7. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20:757-66. (Pubitemid 38019277)
8. O'Farrell A-M, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-605. (Pubitemid 36857948)
9. Pfizer: SUTENT (sunitinib malate) prescribing information [cited 2012 Apr 20]. Available from: http://www.pfizer.com/files/products/ uspi-sutent.pdf
10. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38. (Pubitemid 44528723)
11. DePrimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schöffski P, et al. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Cancer Res 2009;15:5869-77.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
13. DePrimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:32.
14. Harmon CS, DePrimo SE, Raymond E, Cheng AL, Boucher E, Douillard JY, et al. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. J Transl Med 2011;9:120.
15. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26: 1810-16.
16. DeSilva B, Smith W, Weiner R, Kelley M, Smolec J, Lee B, et al. Recommendations for the bioanalytical method validation of ligandbinding assays to support pharmacokinetic assessments of macromolecules. Pharm Res 2003;20:1885-900. (Pubitemid 37449466)
17. Robins JM, Tsiatis A. Correcting for non-compliance in randomized trials using rank-preserving structural failure time models. Commun Stat Theory Methods 1991;20:2609-31.
18. White IR. Uses and limitations of randomization-based efficacy estimators. Stat Methods Med Res 2005;14:327-47. (Pubitemid 41300810)
19. White IR. Estimating treatment effects in randomised trials with treatment switching. Stat Med 2006;25:1619-22.
20. Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 2006;24:1329-31. (Pubitemid 46621994)
21. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006;145:660-64. (Pubitemid 46768841)
22. George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959-68.
23. Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008;26:5352-9.